Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing model. While these policies aim to reshore drug manufacturing and align U.S. drug prices with global benchmarks, they risk disrupting both revenues and profitability...
